NEXI.US Neximmune Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 15, 2026
0.0001 0.0003
Market cap
USD 139.00
P/E
-
P/B
0.00x
ROE
-1,174.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.

Is NEXI.US undervalued?

Graham number

The Graham number of Neximmune Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neximmune Inc fundamental analysis

No fundamental analysis for Neximmune Inc yet.

Neximmune Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neximmune Inc

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials…

Full company profile